ZA965938B - Use of MP52 of MP121 for the treatment and prevention of diseases of the nervous system. - Google Patents

Use of MP52 of MP121 for the treatment and prevention of diseases of the nervous system.

Info

Publication number
ZA965938B
ZA965938B ZA9605938A ZA965938A ZA965938B ZA 965938 B ZA965938 B ZA 965938B ZA 9605938 A ZA9605938 A ZA 9605938A ZA 965938 A ZA965938 A ZA 965938A ZA 965938 B ZA965938 B ZA 965938B
Authority
ZA
South Africa
Prior art keywords
diseases
prevention
treatment
nervous system
nervous
Prior art date
Application number
ZA9605938A
Other languages
English (en)
Inventor
Gertrud Hotten
Jens Pohl
Rolf Bechtold
Michael Paulista
Klaus Unsicker
Original Assignee
Biopharm Ges Zur Biotechnolo G
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopharm Ges Zur Biotechnolo G filed Critical Biopharm Ges Zur Biotechnolo G
Publication of ZA965938B publication Critical patent/ZA965938B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA9605938A 1995-07-12 1996-07-12 Use of MP52 of MP121 for the treatment and prevention of diseases of the nervous system. ZA965938B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19525416A DE19525416A1 (de) 1995-07-12 1995-07-12 Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems

Publications (1)

Publication Number Publication Date
ZA965938B true ZA965938B (en) 1997-02-17

Family

ID=7766658

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9605938A ZA965938B (en) 1995-07-12 1996-07-12 Use of MP52 of MP121 for the treatment and prevention of diseases of the nervous system.

Country Status (8)

Country Link
US (2) US6531450B2 (xx)
EP (1) EP0837938B1 (xx)
JP (1) JPH11509097A (xx)
AU (1) AU6615196A (xx)
DE (1) DE19525416A1 (xx)
ES (1) ES2389624T3 (xx)
WO (1) WO1997003188A2 (xx)
ZA (1) ZA965938B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067637B1 (en) * 1992-02-12 2006-06-27 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Antibody or antibody fragments specific for a protein of the TGF-β family
DE19525416A1 (de) * 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
US6764994B1 (en) * 1993-08-10 2004-07-20 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Growth/differential factor of the TGF-B family
DE19548476A1 (de) * 1995-12-22 1997-06-26 Bioph Biotech Entw Pharm Gmbh Zielgerichtete Verbindungen mit knorpel- und/oder knocheninduzierender Aktivität
DE69740089D1 (de) † 1996-03-22 2011-02-10 Stryker Corp Verfahren zur verbesserten funktionellen Erholung der motorischen Koordiination, der Sprache oder der Sinneswahrnehmung nach Trauma oder Ischämie des ZNS
US7811793B2 (en) * 1996-12-25 2010-10-12 Biopharma Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Process for preparing purified active monomer of bone-derived factor
EP1074620A1 (en) * 1999-08-06 2001-02-07 HyGene AG Monomeric protein of the TGF-beta family
JP2000004882A (ja) * 1998-06-18 2000-01-11 Hoechst Marion Roussel Kk ヒトｍｐ５２遺伝子プロモーターおよびこれを用いた有用物質の探索法
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
EP1289540B1 (en) * 2000-06-01 2012-03-07 Children's Medical Center Corporation Oncomodulin for treating neurological disorders
WO2003000257A1 (fr) * 2001-06-26 2003-01-03 Takeda Chemical Industries, Ltd. Promoteur de production/secretion de la superfamille des tgf-$g(b)
EP1711833A2 (en) * 2004-02-06 2006-10-18 Applera Corporation Preparation of biologically derived fluids for biomarker determination by mass spectrometry
US20060069008A1 (en) * 2004-09-28 2006-03-30 Sanjay Mistry Treatment of neurological deficits in the striatum or substanta nigra pars compacta
KR100775958B1 (ko) * 2005-03-30 2007-11-13 김정문 조직재생 기능을 가지는 비활성 폴리펩티드 및 그 제조방법
WO2006104306A1 (en) * 2005-03-30 2006-10-05 Jung Moon Kim Non-activated polypeptides having a function of tissue regeneration and method for preparing the same
AU2006314713B2 (en) 2005-11-18 2011-10-06 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh High activity growth factor mutants
EP1880731A1 (en) 2006-07-18 2008-01-23 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Human growth and differentiation factor GDF-5
CN101805770B (zh) * 2010-03-12 2012-10-31 南京工业大学 一种利用全细胞生物催化生产环磷酸腺苷的方法
EP2598177B1 (en) 2010-07-30 2015-06-17 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH Drug delivery devices and growth factor formulations for accelerated wound healing
EP2537538A1 (en) 2011-06-22 2012-12-26 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH Bioresorbable Wound Dressing
US11857478B2 (en) 2016-10-03 2024-01-02 Blue Ocean Robotics, ApS Patient lifting robot

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
DE19525416A1 (de) * 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
JP3193050B2 (ja) 1992-02-12 2001-07-30 ビオファルム ゲゼルシャフト ツア ビオテヒノロ ギッシェン エントヴィックルング フォン ファル マカ ミット ベシュレンクテル ハフツング 新規の増殖／分化因子をコード化するｄｎａ配列
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
ES2255059T3 (es) * 1993-12-07 2006-06-16 Genetics Institute, Llc Bmp-12, bmp-13 y composiciones suyas inductoras de tendon.
IL114397A0 (en) 1994-07-01 1995-10-31 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF-beta-family

Also Published As

Publication number Publication date
US20020045568A1 (en) 2002-04-18
WO1997003188A3 (de) 1997-02-27
WO1997003188A2 (de) 1997-01-30
ES2389624T3 (es) 2012-10-29
US7632808B2 (en) 2009-12-15
EP0837938B1 (de) 2012-08-08
AU6615196A (en) 1997-02-10
US20030220248A1 (en) 2003-11-27
EP0837938A2 (de) 1998-04-29
JPH11509097A (ja) 1999-08-17
DE19525416A1 (de) 1997-01-16
US6531450B2 (en) 2003-03-11

Similar Documents

Publication Publication Date Title
ZA965938B (en) Use of MP52 of MP121 for the treatment and prevention of diseases of the nervous system.
ZA961150B (en) Substituted isoxazoles for the treatment of inflammation.
EP0730152A3 (en) Regulation of water treatment agent dosage, based on operating system voltages
ZA978639B (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections.
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
ZA978640B (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis.
EP0592903A3 (en) Use of Ancrod in the manufacture of medications for the treatment of restenosis.
ZA976350B (en) Treatment of liquid.
ZA964198B (en) Treatment regime for skin.
ZA931063B (en) Treatment of glaucoma.
GB2303303B (en) Medical treatment
HU9402578D0 (en) Medicament for treating or preventing cerebrovascular diseases
GB9521725D0 (en) Medical treatment
EP0457671A3 (en) Dipyridamide for the treatment of diseases of the central or peripheral nervous system
ZA964387B (en) Agent for the treatment of radiation injuries
HK1010095A1 (en) Use of 8,9-dehydroestrone for the manufacture of amedicament for the treatment of diseases caused byfree radicals.
GB9420080D0 (en) The treatment of liquids
ZA9610761B (en) Medical treatment.
ZA93348B (en) Treatment of liquids.
PT1011678E (pt) Utilização de mecamilamina para o tratamento de perturbações neuropsiquiátricas responsivas à nicotina.
ZA985818B (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders.
AU6097394A (en) Method for the treatment of respiratory disease
ZA9610264B (en) Preparation for use in the treatment of skin disorders.
EP0579077A3 (en) 1,3,4-thiadiazinones for the treatment of cardiovascular diseases
GB9625560D0 (en) Apparatus for the treatment of liquids